FOXA2 and non-small cell lung carcinoma: First, we observed an increase in FOXA2 expression in NEPC compared with CRPC patient tumors (3, 9, 46) (Figure 1H and Supplemental Figure 2A), LuCaP PDXs (3) (Supplemental Figure 2B), and SCLC compared with non-SCLC (NSCLC) samples (47) (Supplemental Figure 2C).